Tyrx has announced that it has received FDA approval for its antibacterial envelope, AIGISRx N, for use with spinal cord neuromodulators. The product was also recently approved for vagus nerve stimulators and is designed to hold a spinal cord neuromodulator or vagus nerve stimulator securely to provide a stable environment when implanted in the body.
“Surgical site infections are growing much faster than the underlying rate of surgical procedures, with patients often suffering catastrophic consequences,” states Robert White, TYRX president and chief executive officer. “Securing this expanded FDA clearance is another key milestone for TYRX in our quest to reduce surgical site infections where the clinical and economic consequences associated with infection are significant.”
